Vice President Research and Development
Innocan Pharma LTD
Herzliya, Tel Aviv
Dr.Eyal Kalo earned his Ph.D from the Weizmann Institute of Science mastering in the field of cancer research. Eyal completed his studies in 2010 and joined the biotechnology industry where he gained expertise in leading various R&D projects from concept to launch in the field of drug development, medical diagnostics, and natural medicine. Eyal worked as a Chief Scientific Officer at Esense-lab LTD, a pioneering company in the medical cannabis field, specializing in the development of cannabinoids and terpenes formulated into over-the-counter products. Prior to that, Eyal served as a scientific team leader at the molecular diagnostic division of Beckman Coulter and was responsible for the development of an FDA-approved molecular-based diagnostic assay to detect HIV in patients. Prior to that, he served as a senior project manager at IBR Ltd. A company that is under IFF’s structure and develops, manufactures and markets innovative and proprietary natural active ingredients.
P-029 - (Poster #29) Is Long-Acting Synthetic Cannabidiol a Solution to Chronic Pain?
Thursday, September 4, 2025
4:00 PM - 5:30 PM PST